NEOG · Neogen Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 7, 2021; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings Per Share non-GAAP | $0.32 | Full fiscal year 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $177.8M | Full fiscal year 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 20.4% | Full fiscal year 2026 | — |
|
|
|||
| Adjusted Gross Profit non-GAAP | $437.8M | Twelve months ended May 31, 2026 | — |
| Adjusted Net Income non-GAAP | $70.2M | Full fiscal year 2026 | — |
|
|
|||
| Adjusted Operating Expenses non-GAAP | $283.9M | Twelve months ended May 31, 2026 | — |
| Adjusted Operating Income non-GAAP | $153.9M | Twelve months ended May 31, 2026 | — |
| Animal Safety Core Revenue Growth non-GAAP | 0.5% | Q4 FY26 | — |
| Core Growth non-GAAP | 1.9% | Full fiscal year 2026 | — |
| Food Safety Core Revenue Growth non-GAAP | 3.1% | FY26 | — |
| Free Cash Flow non-GAAP | $26.2M | Q4 FY2026 | — |
|
|
|||
| Net debt non-GAAP | $608.2M | As of May 31, 2026 | — |
| Animal Safety Core Growth non-GAAP | -8.7% | Fiscal third quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEOG
this stock
Neogen Corp
|
$2.59B | +73.8% | -2.7% | — | 4.3% |
|
ABT
Abbott Laboratories
|
$196.27B | -8.7% | +5.7% | 31.6 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -3.3% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -2.0% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -45.5% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 7, 2021; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEOG | +6.0% | +23.6% | +7.3% | +0.9% | +73.8% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +6.5% | +20.7% | -4.2% | -2.0% | +61.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.